Rekvina Laboratories generates its first revenue as losses persist

What's new with Rekvina Laboratories Ltd.

• Rekvina reported its first-ever annual revenue of ₹126.54 lakh for FY26.
• The company remains in the red with a net loss of ₹25.47 lakh.
• The board reiterated existing plans for its acquisition of Radiant Parenterals Ltd.

Why this matters for Rekvina Laboratories Ltd.

Revenue generation is a nominal step for a startup, but the company's reliance on loss-making operations indicates it is still in a formative stage. Since the strategic updates are recycled news, the filing lacks the necessary catalysts to shift the firm's current profile.

What we're watching

• Whether the Radiant Parenterals acquisition provides a path to profitability.
• Update on the previously announced preferential share issuance.
• Any sign of revenue growth scaling in upcoming quarterly filings.

The full read

Rekvina Laboratories has closed its books for FY26, posting its first **₹126.54 lakh** in revenue. Despite this milestone, the company remains unprofitable with a net loss of **₹25.47 lakh**. The filing confirms the company is still pursuing its acquisition of Radiant Parenterals and a related preferential share issue, both of which were already known to the market. Routine results like these from a nano-cap rarely move the dial. The company is at the starting gate of commercial operations. For now, the narrative holds few surprises. The next test is how efficiently the company integrates its recent acquisition and whether it can flip its loss-making trajectory in the coming year.